Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
13 papers
Recent·Most cited
R. Nameki, H. Chang, P. H. Yu, F. Abbasi, X. Lin, J. Reddy, M. Haro, M. Fonseca, M. L. Freedman, R. Drapkin, R. Corona, K. Lawrenson
This study identifies MECOM, PAX8, SOX17, and WT1 as master regulators in HGSC, showing their rewired cistromes and tumor-specific inhibition potential.
bioRxiv · Apr 11, 2023 · PreprintCancer Biology
J. Conway, A. K. Tewari, S. Y. Camp, S. Han, J. Crowdis, M. X. He, Y. A. Nyame, S. H. AlDubayan, N. Schultz, Z. Szallasi, M. M. Pomerantz, M. L. Freedman, L. Fong, P. S. Nelson, M. Brown, , E. Van Allen
This study analyzes prostate cancer clonal architecture and evolutionary dynamics in 845 tumors, finding that Black patients have more monoclonal tumors but higher recurrence rates, and identifies new mutational signatures linked to subclones.
bioRxiv · Mar 23, 2023 · PreprintCancer Biology
A. Armaos, F. Serra, I. Nunez Carpintero, J. H. Seo, S. C. Baca, S. Gustincich, A. Valencia, M. L. Freedman, D. Cirillo, C. Giambartolomei, G. G. Tartaglia
PENGUIN reconstructs protein interactions at enhancer-promoter regions and identifies cancer-associated SNPs in prostate cancer cell lines.
bioRxiv · Oct 20, 2022Cancer Biology
N. De Sarkar, R. D. Patton, A.-L. Doebley, B. Hanratty, A. J. Kreitzman, J. F. Sarthy, M. Ko, M. Adil, S. Brahma, M. P. Meers, D. H. Janssens, L. S. Ang, I. Coleman, A. Bose, R. F. Dumpit, , G. Ha
This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.
bioRxiv · Jun 21, 2022Cancer Biology
A. Nardone, X. Qui, A. Feiglin, X. Fu, S. Spisak, A. Feit, G. Cohen Feit, Y. Xie, A. Font-Tello, C. Guarducci, F. Hermida Prado, S. Syamala, K. Lim, M. Pun, M. Cornwell, , R. Jeselsohn
This study identifies a unique chromatin state in invasive lobular breast cancer (ILC) driven by FOXA1-ER axis, leading to tamoxifen resistance and poor outcomes.
bioRxiv · Mar 29, 2022Cancer Biology
X. Lu, K. W. Fong, G. Gritsina, F. Wang, S. C. Baca, J. Berchuck, J. Ross, E. Corey, W. Catalona, N. S. Chandel, X. Yang, M. L. Freedman, J. C. Zhao, J. Yu
This study identifies HOXB13's AR-independent role in suppressing lipogenesis via HDAC3-mediated epigenetic repression, linking its loss to metastatic prostate cancer progression.
bioRxiv · Oct 4, 2021Cancer Biology
J. H. Hwang, R. Arafeh, J.-H. Seo, S. C. Baca, M. Ludwig, T. E. Arnoff, C. Richter, H. E. Bergom, S. McSweeney, J. P. Rennhack, S. A. Klingenberg, A. T. Cheung, J. Kwon, J. So, S. Kregel, , W. Hahn
This study identifies CREB5 as a key driver of resistance to androgen receptor targeting therapies by reprogramming nuclear interactions and activating TGFβ and Wnt signaling pathways.
bioRxiv · Aug 18, 2021Cancer Biology
A. Shetty, J.-H. Seo, C. A. Bell, E. P. O'Connor, M. Pomerantz, M. L. Freedman, A. Gusev
This study identifies allele-specific epigenetic activity in prostate cancer and normal tissue, linking it to GWAS risk loci and highlighting tumor-specific regulatory elements.
bioRxiv · Jun 2, 2021Cancer Biology
S. C. Baca, D. Y. Takeda, J.-H. Seo, J. Hwang, S. Y. Ku, R. Arafeh, T. Arnoff, S. Agarwal, C. Bell, E. O'Connor, X. Qiu, S. Abu Alaiwi, R. I. Corona, M. A. S. Fonseca, C. Giambartolomei, , M. L. Freedman
The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.
bioRxiv · Oct 23, 2020Cancer Biology
Z. Bakouny, D. A. Braun, S. A. Shukla, W. Pan, X. Gao, Y. Hou, A. Flaifel, S. Tang, A. Bosma-Moody, M. X. He, N. Vokes, J. Nyman, W. Xie, A. H. Nassar, S. Abou Alaiwi, , T. H. Ho
This study characterizes the molecular features and immune profile of sarcomatoid and rhabdoid renal cell carcinoma, showing their responsiveness to immune checkpoint inhibitors and identifying key genetic and transcriptional determinants.
bioRxiv · May 28, 2020Cancer Biology
J. Reddy, M. A. S. Fonseca, R. I. Corona, R. Nameki, F. Segato Dezem, I. A. Klein, H. Chang, D. Chaves-Moreira, L. Afeyan, T. M. Malta, X. Lin, F. Abbasi, A. Font-Tello, T. Sabedot, P. Cejas, , K. Lawrenson
This paper introduces CaCTS, an algorithm that identifies candidate master transcription factors (MTFs) across 34 cancer types using RNA-seq data, revealing novel MTFs and functional groupings.
bioRxiv · Nov 12, 2019Cancer Biology
A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis
This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.
bioRxiv · Aug 8, 2019 · PreprintCancer Biology
R. I. Corona, J.-H. Seo, X. Lin, D. J. Hazelett, J. Reddy, F. Abassi, Y. G. Lin, P. Y. Mhawech-Fauceglia, J. Lester, S. P. Shah, D. G. Huntsman, A. Gusev, B. Y. Karlan, B. P. Berman, M. L. Freedman, , K. Lawrenson
The paper identifies histotype-specific regulatory elements in ovarian cancer by integrating chromatin landscapes and somatic mutations, highlighting the PAX8 pathway's role in tumor development.
bioRxiv · Feb 1, 2019Cancer Biology